Heron Therapeutics Inc vs Western Union Co — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Western Union Co trades at $8.49 (market cap $2.71B). The key difference: Western Union Co is far larger — about 29.6× Heron Therapeutics Inc's market cap, and Western Union Co pays a 10.85% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WU | |
|---|---|---|
Market Cap | $91.46M | $2.71B |
Sector | Health | Technology |
52-Week High | $1.96 | $10.28 |
52-Week Low | $0.39 | $7.04 |
Enterprise Value | $189.36M | $2.40B |
Dividend Yield | — | 10.85% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Western Union (WU) trades at $8.65, down 2.59% on the day, with strong valuation metrics including a P/E of 6.53 and P/S of 0.71. The company maintains profitability with a 10.88% net margin and 47.66% ROE, though Q1 2026 earnings missed expectations. Recent developments include strategic partnerships with Total Wireless and Bybit, and the pending acquisition of Intermex. Technical indicators show mixed signals with bullish moving averages but overbought RSI levels.
WU presents a value opportunity with attractive dividend yield and low valuation multiples, but faces revenue decline and margin pressure. The stock trades above analyst consensus target of $7.83, suggesting limited near-term upside. Key risks include declining traditional remittance business and execution challenges in digital transformation. Institutional sentiment remains cautious with only 12.5% buy ratings.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →